Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? [electronic resource]
Producer: 20070207Description: 1379-85 p. digitalISSN:- 0923-7534
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Capecitabine
- Carcinoma -- drug therapy
- Deoxycytidine -- administration & dosage
- Docetaxel
- Dose-Response Relationship, Drug
- Female
- Fluorouracil -- administration & dosage
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Metastasis -- drug therapy
- Survival Analysis
- Taxoids -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.